10/16/20151 UROTHELIAL CANCER E. Elamin, MD. 10/16/20152 Bladder : Ureters: Renal Pelvis Bladder :...
-
Upload
julia-charleen-gibson -
Category
Documents
-
view
223 -
download
1
Transcript of 10/16/20151 UROTHELIAL CANCER E. Elamin, MD. 10/16/20152 Bladder : Ureters: Renal Pelvis Bladder :...
04/20/2304/20/23 11
UROTHELIAL UROTHELIAL CANCERCANCER
E. Elamin, MDE. Elamin, MD
04/20/2304/20/23 22
Bladder :Bladder : Ureters:Ureters: Renal PelvisRenal Pelvis
50 :50 : 3 :3 : 11
04/20/2304/20/23 33
EpidemiologyEpidemiology
2005: 63,000 new cases (13,000 2005: 63,000 new cases (13,000 death)death)
Male:Female: 3:1Male:Female: 3:1 Incidence: increasing (aging)Incidence: increasing (aging) Age: >65 yrsAge: >65 yrs
04/20/2304/20/23 44
Risk FactorsRisk Factors Smoking: 80% of casesSmoking: 80% of cases Occupational:Occupational:
Aniline Dye, Rubber workers, Painters Aniline Dye, Rubber workers, Painters
Drugs: Drugs: Phenacetin, oral cytoxan Phenacetin, oral cytoxan
Upper U tract TCC: 30-50% risk of Upper U tract TCC: 30-50% risk of bladder cabladder ca
Bladder TCC: 2-3% risk of Upper U Tract caBladder TCC: 2-3% risk of Upper U Tract ca
Chronic irritation/infection:Chronic irritation/infection: Schistosomiasis, UTIsSchistosomiasis, UTIs
Balkan nephropathyBalkan nephropathy
04/20/2304/20/23 55
ScreeningScreening??
Dipstick for microhemturiaDipstick for microhemturiaMessing et al. Urology 45;1995Messing et al. Urology 45;1995
04/20/2304/20/23 66
Clinical presentationClinical presentation
Hematuria (painless)Hematuria (painless) Irritable bladder symptoms: TisIrritable bladder symptoms: Tis Urinary voiding symptoms Urinary voiding symptoms Symptoms of advanced dzSymptoms of advanced dz
04/20/2304/20/23 77
DiagnosisDiagnosis Cystoscopy
Papillary exophyticErythema/edema of mucosa: High
grade, invasive
IVP, Retrograde pyelogram Bimanual exam (EUA) US, CT, Bone scan, MRI
04/20/2304/20/23 88
BiopsyBiopsy
Biopsy of the primary tumor must include Biopsy of the primary tumor must include muscle if possiblemuscle if possible
Biopsy of selected mucosal sites to detect Biopsy of selected mucosal sites to detect possible concomitant Tispossible concomitant Tis
04/20/2304/20/23 99
PATHOLOGYPATHOLOGY
TCC: 90 - 95%TCC: 90 - 95% Sq CC: 3 - 7% Sq CC: 3 - 7%
• Renal pelvis and uretersRenal pelvis and ureters Adeno: < 3%Adeno: < 3%
• Trigone Trigone
• Dome: UrachalDome: Urachal
04/20/2304/20/23 1010
Carcinoma in SituCarcinoma in Situ
Usually accompany higher Disease stageUsually accompany higher Disease stage MultifocalMultifocal Considered Aggressive if:Considered Aggressive if:
• Associated with superficial tumorsAssociated with superficial tumors• DiffuseDiffuse
04/20/2304/20/23 1111
PROGNOSTIC PROGNOSTIC FEATURESFEATURES
GradeGrade TNM stageTNM stage
• T2 (Muscle invasion): 20-50% 5YST2 (Muscle invasion): 20-50% 5YS
• N +ve: 0-20% 5YSN +ve: 0-20% 5YS
04/20/2304/20/23 1212
TNM stagingTNM staging Tx Primary tumor cannot be assessed T0 No evidence of primary tumor Ta Noninvasive papillary tumor Tis Carcinoma in situ: “flat tumor” T1 Tumor invades subepithelial connective
tissue T2 Tumor invades muscle
• pT2a Tumor invades superficial muscle (inner half)
• pT2b Tumor invades deep muscle (outer half)
T3 Tumor invades perivesical tissue• pT3a Microscopically• pT3b Macroscopically (extravesical
mass) T4 Tumor invades any of the following:
prostate, uterus, vagina, pelvic wall, abdominal wall
• T4a Tumor invades prostate, uterus, vagina
• T4b Tumor invades pelvic wall, abdominal wall
Nx Regional lymph nodes cannot be assessed N0 No regional node involvement
N1 Metastasis in a single node, ≤ 2 cm in greatest dimension
N2 Metastasis in a single node, > 2 cm but ≤ 5 cm in greatest dimension; or multiple lymph nodes, none > 5 cm in greatest dimension
N3 Metastasis in a lymph node, > 5 cm in greatest dimension
Mx Distant metastasis cannot be assessed M0 No distant metastasis M1 Distant metastasis
Stage grouping Stage 0a Ta N0 M0 Stage 0is Tis N0 M0 Stage I T1 N0 M0 Stage II T2a N0 M0 T2b N0 M0 Stage III T3a N0 M0 T3b N0 M0 T4a N0 M0 Stage IV T4b N0 M0 Any T N1-N3 M0 Any T Any N M1
04/20/2304/20/23 1313
NON-INVASIVENON-INVASIVEWork-upWork-up
Imaging of upper tract collecting system Cytology x 1 Consider pelvic CT before TURBT if sessile
or high grade
04/20/2304/20/23 1414
NON-INVASIVENON-INVASIVE
Examination Under Anesthesia (bimanual) TURBT If sessile, high grade or suspicious for CIS:
Random biopsy Consider TUR biopsy of prostate
04/20/2304/20/23 1515
Muscle-invasiveMuscle-invasivework-upwork-up
CBC, CMP Chest x-ray Imaging of upper tract collecting system Abdominal/pelvic CT or MRI Examination under anesthesia/cystoscopy TURBT Bone scan if alkaline phosphatase elevated or
symptoms
04/20/2304/20/23 1616
METASTATICMETASTATICwork-upwork-up
CBC, CMP Chest CT Abdominal/pelvic CT or MRI Bone scan ECG Creatinine clearance
04/20/2304/20/23 1717
TREATMENTTREATMENT
04/20/2304/20/23 1818
Superficial Disease Papillary noninvasive (Ta) and T1:
• Few lesions: TUR
• 5 yr Survival rate: 70%
• Multiple, >5 cm, Recurrent, +CIS: TUR +
04/20/2304/20/23 1919
Papillary or solid
cTa, G1-2:• Observe or • Single dose intravesical chemo within 24 hours
(not immunotherapy) • Cystoscopy at 3 m
• increasing interval as appropriate
04/20/2304/20/23 2020
Papillary or solid cTa, G3 and cT1, G1-2:
• Observe or intravesical chemo• BCG (preferred) or Mitomycin
cT1, G3:• Uncertain complete resection based on:
Size/location No muscle in specimen Inadequate staging Lymphovascular invasion
• Reresect or Cystectomy: If –ve: BCG or Mitomycin If +ve BCG or Cystectomy
• Completely resected: BCG or Mitomycin or Consider cystectomy
04/20/2304/20/23 2121
Any CIS/Tis(abnormal mucosa)
BCGBCG Cystoscopy and urine cytology q 3 m for 2 y
Then q 6 m for 2 y then annually
Imaging of upper tract collecting system q 1–2 y Urinary urothelial tumor markers (optional)
04/20/2304/20/23 2222
Intravesical TreatmentIntravesical Treatment Indications:Indications:
• Multiple T1Multiple T1• Multifocal Ta, (G2-3)Multifocal Ta, (G2-3)• Diffuse TisDiffuse Tis• Rapidly recurring dzRapidly recurring dz
Cytotoxic agents: Mitomycin, Adriamycin, Cytotoxic agents: Mitomycin, Adriamycin, ThiotepaThiotepa• Reduce recurrence rateReduce recurrence rate
Immune modulator: BCG (Tis)Immune modulator: BCG (Tis)• Decrease progression rateDecrease progression rate
04/20/2304/20/23 2323
? Cystectomy for Superficial Dz? Cystectomy for Superficial Dz
Large tumorsLarge tumors Some high G Some high G Impractical TUR Impractical TUR
multiple tumorsmultiple tumors Multiple recurrencesMultiple recurrences
Diffuse Tis unresponsive to intravesical Diffuse Tis unresponsive to intravesical therapytherapy
Prostatic stromal involvementProstatic stromal involvement
04/20/2304/20/23 2424
POST-TREATMENT Ta, T1, CISPERSISTANT OR RECURRENT DISEASE
Cystoscopy +ve: TURBT Adj therapy based on tumor and G
Cytology positive, Imaging negative, Cystoscopy –ve:• Random bx:
-ve: Follow-up q 3 m or Maintenance BCG +ve: BCG (maintenance BCG, if complete response)
• If incomplete response: Cystectomy or Other intravesical chemo or immunotherapy
04/20/2304/20/23 2525
Recurrence post-intravesical treatment with BCG or MMC; no more than 2 consecutive cycles
CR CR Maintenance BCG (optional) Tis or Ta:
• Change intravesical agent or• Cystectomy
T1G3:• Cystectomy
04/20/2304/20/23 2626
Papillary or solidF/UF/U
Cystoscopy and urine cytology q 3 m for 2 y Then q 6 m for 2 y then annually
Imaging of upper tract collecting system q 1–2 y
Urinary urothelial tumor markers (optional)
04/20/2304/20/23 2727
PROBABILITY OF RECURRENCE AND PROGRESSION
Pathology Probability of Recurrence Probability of Progression to Muscle-Invasive
Ta, G1 50% Minimal
Ta, G2 50% Low
Ta, G3 60% Moderate
T1, G2 50% Moderate
T1, G3 70% High
CIS 50%–90% High
04/20/2304/20/23 2828
Invasive CancerInvasive Cancer CystectomyCystectomy
Partial cystectomy:Partial cystectomy:• Single tumor without CISSingle tumor without CIS
Radical cystectomyRadical cystectomy• Overall 5-ys S:Overall 5-ys S: 50%50%
• Recurrence rate:Recurrence rate: 10-20%10-20%
Bladder preservation:Bladder preservation: TURBT TURBT →→ RT/Chemo RT/Chemo
• Salvage CystectomySalvage Cystectomy
04/20/2304/20/23 2929
cT2TREATMENT
Radical cystectomy • consider neoadj chemo in selected pts• Consider adj chemo if no neoadj treatment given
(+ve LN, pT3)
Segmental cystectomy (solitary lesion in a suitable location; no CIS)• Consider adj RT or chemo (+ve LN, +ve margin,
high G, pT3)
04/20/2304/20/23 3030
cT2cT2TREATMENTTREATMENT
Selective bladder sparing following maximal TUR (only if no hydronephrosis); Chemotherapy/RT• Evaluate with cystoscopy and TURBT
+ve: Radical cystectomy -ve: Observation and/or Chemo/RT and/or Adj chemo
04/20/2304/20/23 3131
cT2cT2TREATMENTTREATMENT
Highly selected pts with extensive comorbid diseases or poor PS:• TURBT alone or RT alone or Chemo alone:
Evaluate with cystoscopy and TURBT
• +ve: Radical cystectomy
• -ve: Observation and/or Chemo+ RT and/or Adj chemo
04/20/2304/20/23 3232
If TURBT aloneIf TURBT alone
Aggressive re-resection of the site within 4 weeks of the primary procedure to ensure that there is no residual disease.
If the repeat TURBT is -ve, repeat cysto every 3 months until a relapse is documented.
04/20/2304/20/23 3333
RT or Chemotherapy alone RT or Chemotherapy alone is not considered adequate and standard without additional treatment to the bladder and remains investigational
04/20/2304/20/23 3434
cT3, N0cT3, N0
Radical cystectomy, consider neoadj chemo:• Consider adj chemo (pT3, +ve LN) if no neoadj
treatment given Selective bladder sparing following maximal
TURBT; chemo/RT:• cystoscopy, cytology and TURBT
-ve: Observe and/or Consolidation chemo/RT and/or Adj chemo
+ve: Cystectomy or salvage therapy
04/20/2304/20/23 3535
Bladder-sparingBladder-sparing
Reasonable alternative to cystectomy for pts: who are medically unfit for surgery who seek an alternative
No hydronephrosis. Mets must be excluded. Complete TURBT as safely as possible Exam Under Anesthesia
04/20/2304/20/23 3636
Muscle-invasiveConcurrent ChemoRT
Complete TURBT Induction ohase:
• 40 Gy of external beam RT + Two doses of cisplatin on weeks 1 and 4. Repeat cysto:
• If residual disease, a cystectomy is advised. • If is no visible disease and the cytology and biopsy are negative (T0):
Add 25 Gy of external-beam RT + one dose of cisplatin.
70% of pts were rendered tumor-free in the bladder at the initial 70% of pts were rendered tumor-free in the bladder at the initial post-treatment cystoscopy exam.post-treatment cystoscopy exam.• About 1/4 developed a new superficial or invasive lesion requiring About 1/4 developed a new superficial or invasive lesion requiring
additional therapyadditional therapy
04/20/2304/20/23 3737
cT4a - T4b, N0cT4a - T4b, N0
Chemo or Chemo/RT:• Good response: Consider consolidation chemo +/-
RT or Surgery
Surgery ± chemo (select cT4a pts only)
04/20/2304/20/23 3838
NeoAdj ChemotherapyNeoAdj Chemotherapy
MVACx2->surg ->MVACx3 orMVACx2->surg ->MVACx3 or Surgery -->MVACx5Surgery -->MVACx5
• 58% DFS58% DFS SWOG 8710: Neoadj MVACx3 vs SWOG 8710: Neoadj MVACx3 vs
cystectomy:cystectomy:• 5YS: 57% vs 42%5YS: 57% vs 42%• MS: 6.2 vs 3.8YMS: 6.2 vs 3.8Y
04/20/2304/20/23 3939
Always biopsy enlarged LN Always biopsy enlarged LN if technically possible and if technically possible and no distant mets.no distant mets.
04/20/2304/20/23 4040
Muscle invasiveMuscle invasiveF/UF/U
LFTs, Cr, electrolytes, C-x-ray q 6-12 m Collecting system imaging at baseline and q 2 y CT at baseline and q 3-6 m for 2 y, then as indicated If bladder sparing:
• cystoscopy + cytology ± biopsy q 3 m x 4, then increasing intervals If cystectomy:
• urine cytology q 6-12 m If cystectomy + cutaneous diversion:
• urethral wash cytology q 6-12 m If cystectomy + continent orthotopic diversion:
• Vit B12 annually
04/20/2304/20/23 4141
Muscle invasiveMuscle invasiveRECURRENCERECURRENCE
Local recurrence, Preserved bladder:• Invasive:
Cystectomy or salvage chemo or RT or Palliative TURBT
• Tis, Ta, or T1: Intravesical BCG or cystectomy
04/20/2304/20/23 4242
Muscle invasiveMuscle invasiveRECURRENCERECURRENCE
+ve cytology, Preserved bladder (Cystoscopy, EUA, random biopsy -ve):
Retrograde selective washings of upper tract, prostatic urethra biopsy
Metastatic or local recurrence postcystectomy: Chemo and/or RT
04/20/2304/20/23 4343
Relapses in the Bladder After Relapses in the Bladder After Bladder-Sparing ApproachesBladder-Sparing Approaches
Invasive disease:• 2nd attempt of bladder preservation is not advisable.• Radical cystectomy:
Salvage cystectomy may not be possible for pts who has received a full course RT (> 65 Gy) and has bulky residual disease.
• salvage non-cross-resistant chemo is advised
04/20/2304/20/23 4444
Mets: pN +veMets: pN +ve
Chemo or Chemo/RT:
• Cystoscopy:Cystoscopy: -ve: -ve: Observe or Boost with RT or Surgery +ve: Salvage therapy+ve: Salvage therapy
04/20/2304/20/23 4545
High Risk/Locally AdvancedHigh Risk/Locally Advanced(T3-4, vascular invasion, N+ve)(T3-4, vascular invasion, N+ve)
Cystectomy; 20-30% cure rateCystectomy; 20-30% cure rate MVACx2 MVACx2 →→Surg Surg →→ MVACx3 MVACx3 Surg Surg →→ MVAC MVAC
58% DFS58% DFS
04/20/2304/20/23 4646
Mets: DisseminatedMets: Disseminated
ChemotherapyChemotherapy
04/20/2304/20/23 4747
ChemotherapyChemotherapyMetastatic DiseaseMetastatic Disease
CisCA:CisCA: MVAC: MVAC: RR=39%RR=39%
• MVAC vs CisCA: MVAC vs CisCA: RR = 65% vs 46%RR = 65% vs 46%
CMVCMV CisplatinCisplatin Taxol:Taxol: RR=42%RR=42% CarboTaxol: CarboTaxol: RR=52%RR=52% Gemzar:Gemzar: RR=27%RR=27% Gemzar/Cis:Gemzar/Cis: RR=66%RR=66% TaxolCisIfex:TaxolCisIfex:
04/20/2304/20/23 4848
NON-TRANSITIONAL CELL CARCINOMA (TCC)NON-TRANSITIONAL CELL CARCINOMA (TCC)
Same as TCC management with the following issues:• Mixed Histology:
Complete response less likely with bladder sparing• Pure Squamous:
Cystectomy or RT• Adenocarcinoma:
MVAC ineffective Cystectomy or partial cystectomy Consider 5-FU-based therapy Urachal tumors require complete urachal resection
• Small-cell: Neoadjuvant or adjuvant small-cell chemo regimens Local treatment (surgery, RT)
04/20/2304/20/23 4949
PRINCIPLES OF CHEMOTHERAPYPRINCIPLES OF CHEMOTHERAPY
MVAC:• Toxicities limit its use• Historical standard of care based on improved survival and
response rates when compared to older regimens. Gemcitabine/cisplatin
• Not inferior to MVAC in terms of survival.• Favorable toxicity profile. • standard 1st choice for most pts.
Alternative Regimens• Cisplatin/paclitaxel• Gemcitabine/paclitaxel• Carboplatin/paclitaxel
04/20/2304/20/23 5050
PRINCIPLES OF CHEMOTHERAPYPRINCIPLES OF CHEMOTHERAPY
Adj: At least 4 cycles of a cisplatin-based chemo (eg. M-VAC).
Adj for High Risk pts:• T2 tumors with nodal involvement
• high-G
• transmural invasion, or vascular invasion
• P53 positive
No data support the use of adj chemo for non-TCC, regardless of stage.
04/20/2304/20/23 5151
PRINCIPLES OF R.T. OF PRINCIPLES OF R.T. OF INVASIVE DISEASEINVASIVE DISEASE
RT is rarely appropriate for pts with recurrent superficial tumors or diffuse CIS.
Precede RT by maximal TURBT. Concurrent chemoRT is encouraged. Simulate and treat pts with the bladder empty. Use multiple fields from high-energy linear accelerator
beams. Treat the whole bladder with or without pelvic LN with
40-55 Gy and then boost the bladder tumor to a total dose of 64-66 Gy.
04/20/2304/20/23 5252
Upper GU Tract Upper GU Tract TumorsTumors
04/20/2304/20/23 5353
Renal pelvisRenal pelvis
Operable Low grade:• Nephroureterectomy with cuff of bladder• Nephron-sparing procedure• Endoscopic resection ± postsurgical intrapelvic chemo
or BCG Operable High G, large, or parenchymal invasion:
• Nephroureterectomy with cuff of bladder + regional lymphadenectomy
Metastatic:• Chemotherapy
04/20/2304/20/23 5454
TCC ureterTCC ureter Upper:
• Nephroureterectomy with cuff of bladder and regional lymphadenectomy if high G or
• Endoscopic resection Mid Low G:
• Excision and ureteroureterostomy or• Endoscopic resection or• Nephroureterectomy with cuff of bladder
Mid High G:• Nephroureterectomy with cuff of bladder and Regional
lymphadenectomy Distal:
• Distal ureterectomy and reimplantation of ureter or• Endoscopic resection or• Nephroureterectomy with cuff of bladder and Regional
lymphadenectomy if high grade
04/20/2304/20/23 5555
Upper GU Tract TumorsUpper GU Tract TumorsAdj TherapyAdj Therapy
pT0, pT1: None
pT2, pT3, pT4, pN+: Consider adjuvant chemo
04/20/2304/20/23 5656
Upper GU Tract TumorsUpper GU Tract TumorsF/UF/U
Cystoscopy every 3 m for 1 y, then at increasing intervals
Upper tract imaging 1-2 y Ureteroscopy 3-12 m intervals if endoscopic
resection ± CT scan or MRI ± Chest x-ray
04/20/2304/20/23 5757
Urothelial Carcinoma of the ProstateUrothelial Carcinoma of the Prostate
Stromal invasion:• Cystoprostatectomy ± urethrectomy
• Consider adj chemo Ductal + acini:
• Cystoprostatectomy ± urethrectomy or
• TURP and BCG Prostatic urethra:
• TURP + BCG or
• Cystoprostatectomy± urethrectomy for recurrence